The Federal Government, through the National Agency for Food and Drug Administration and Control (NAFDAC), has disposed of substandard goods, including counterfeit medications and medical devices, valued at N43 billion in Ibadan, the capital of Oyo State.

This operation took place on Thursday at the Moniya dump site in the Akinyele Local Government area, with representatives from security agencies and the Oyo State Government present.

Professor Mojisola Adeyeye, the Director-General of NAFDAC, was represented by Shabba Mohammed, the Director of Investigation and Enforcement.

He stated that the products were voluntarily handed over to the agency by compliant companies, non-governmental organizations, and trade unions.

Adeyeye elaborated on the extensive measures that led to the seizure of numerous pharmaceutical products, both registered and unregistered, following various raids in multiple locations.

The confiscated items included aphrodisiacs, sex enhancement drugs, over-the-counter medications, and prescription-only drugs.

The NAFDAC Director-General emphasized the critical role of public participation in the fight against counterfeit drugs and unsafe food products, urging citizens to report illegal activities to the nearest NAFDAC office for prompt investigation.

“In total, over thirty different products were seized,” she remarked, noting that the confiscated items included prohibited substances such as codeine and narcotics, with a cumulative value exceeding N48 million.

“The agency has been diligently collecting intelligence on the illegal storage, sale, and distribution of narcotics by pharmaceutical vendors in Lagos and other states.”

“Recent operations conducted by the Investigation and Enforcement Directorate led to the seizure of products worth over N700 million.

In addition to counterfeit pharmaceuticals, the initiative also targeted contraband items such as unregistered soaps, tomato paste, and fake beverages.”

“By taking these actions, NAFDAC aims to protect the health and safety of the public while promoting compliance within the pharmaceutical industry,” she stated.